Objective Neuroendocrine carcinomas (NECs) are rare neoplasms with an increasing incidence. Oncogenetic pathways of colorectal NEC are still poorly understood, and no treatment standards are available for these rare tumors.
Results
At the time of diagnosis, the mean age of the patients was 60 years (40-79) and 10 patients had synchronous metastases. A transient response occurred in two patients and one patient treated with cisplatinetoposide or fluoropyrimidine-oxaliplatin, respectively. Tumor progression-related death occurred in 11 of 12 patients. Ten tumors contained an exocrine component, accounting for 5-70% of the tumor, and the other two contained an amphicrine component. BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF V600E (n = 2) or KRAS G12D (n = 2), KRAS G12V or KRAS G13D . DNA was obtained from both exocrine and endocrine components in seven cases, and the BRAF/KRAS status was identical in all cases. Split of the ALK locus was detected in a minority of tumor cells in two of eight cases, but EML4-ALK transcripts were absent. 
Introduction
The prevalence of neuroendocrine tumors (NET) has increased markedly over the past three decades according to the US Surveillance Epidemiology and End Results database. However, the outcomes have not improved over a similar period [1] . Rectal NET accounts for 12.6% of all NET. At diagnosis, 50% of NET of the rectum are asymptomatic and 80% are less than 1 cm in size. The 5-year survival rate is 88.3%. NET of the colon comprise 7.8% of all NET, and occur most frequently in the cecum. Their prognosis is the worst of the NET, with an overall 5-year survival of 33-42% without stratification by the degree of differentiation [2] .
According to the 2010 WHO classification of digestive tumors, neuroendocrine carcinomas (NECs) correspond to grade G3 NET [3] . The diagnosis of NEC relies on a high mitotic count or a high proliferation index [4] . Among NEC, some tumors also contain an exocrine component, and are reported as mixed adenoneuroendocrine carcinomas (MANEC), when both exocrine and neuroendocrine components represent more than 30% [3, 5, 6] . Mixed endocrine-exocrine tumors of the gut constitute a heterogeneous group of rare neoplasms, which may include different histopathologic and prognostic classes [7] . These tumors have received several eponyms, such as mixed carcinoid-adenocarcinoma, composite carcinoma, collision carcinoma, combined carcinoma, and adenoendocrine carcinoma . In most cases, neuroendocrine and exocrine components are different components of the tumor. However, some carcinomas correspond to the proliferation of amphicrine cells, which share both neuroendocrine and exocrine characteristics.
We carried out a retrospective analysis of colorectal NEC treated in our institution to determine the clinical, pathological, and molecular characteristics of these rare tumors, as well as response to treatment. KRAS and BRAF mutations were analyzed because of their frequency in colorectal carcinomas [35] . EML4-ALK translocation was also analyzed because it was recently reported in colorectal NET [36] .
Methods

Patients' selection
The records of patients with histologically proven NEC were retrieved from the files of the pathology departments of Ambroise Pare University Hospital (Boulogne) and the University Hospital of Angers. Patients who had a tumor of the appendix were excluded. The following clinical data were collected: age, sex, primary tumor location, presence of synchronous or metachronous metastases, type and number of metastatic sites, type and number of metastatic chemotherapy (CT) regimen received (with dates of initiation, treatment duration, and best tumor response with the date of onset and duration), and the reasons for stopping a CT regimen (toxicity, clinical progression, progression proved by a CT scan, or other reasons).
We classified the various CT regimens used into four categories, as follows:
(1) 'VP16-CDDP' including regimens combining etoposide and cisplatin: every 3 weeks, a 1-h infusion of 100 mg/m 2 of etoposide-VP16 on days 1-3 and a 1-h infusion of 50 mg/m 2 of CDDP on day 1; (2) 'XELOX' including regimens combining oxaliplatin and capecitabine: every 3 weeks, a 2-h infusion of 130 mg/m 2 of oxaliplatin on day 1 and 1600 mg/m 2 of capecitabine orally twice daily for 14 days; The response rates to CT were evaluated by spiralcomputerized tomography according to the RECIST criteria. The overall survival for all patients was defined as the time between histological diagnosis and the date of death or the last follow-up.
Histological and immunohistochemical evaluations
Diagnoses were made between 1996 and 2008. Only the patients for whom slides, paraffin-embedded tumor samples, and medical records were available were included. The study was carried out in accordance with French ethical laws and recommendations. Molecular analysis was carried out for clinical purposes for patients who were alive, and approved by the ethics committee for patients who died (no. 12 01 08, DC 2009-933). Histology review was carried out for all the patients by at least two of the pathologists in the study (J.F.E. and R.K.). For all the tumors, stainings with hematoxylin and eosin (H&E) and alcian blue (pH 2.5) were carried out. 37 mm field diameter), and these counts were expressed per 10 high-power fields (HPF).
Molecular analyses
Tumor DNA was extracted from formalin-fixed and paraffin-embedded (FFPE) tissues of the primary tumors. For each sample, four serial sections were performed. The first one (4 mm thick) was stained with H&E for histology control and selection of the areas of each tumor component, and the three others (20 mm thick) were used for dissection at Â 10 magnification. Tumor DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Les Ulis, France) after proteinase K digestion. The DNA concentration was determined by spectrophotometry (Nanodrop; Thermo Scientific, Courtaboeuf, France) and adjusted to 10-30 ng/ml for further analyses. Detection of hot spot mutations in codon V600 of BRAF was carried out by pyrosequencing on PyroMark Q24 (Qiagen). The primer sequences are presented in Table 1 . Detection of hot spot mutations in exons 12 and 13 of KRAS was carried out by real-time PCR, as described [37] . The sequence references of KRAS and BRAF cDNA were, respectively, GenBank NM_004985.3 and GenBank NM_004333.4.
The detection of chromosomal rearrangements involving ALK was carried out by in-situ hybridization with an ALK break-apart probe set [Vysis LSI ALK Dual Color Break Apart Rearrangement FISH probe kit (06N43-020) (Abbott Molecular, Rungis, France)]. Assays were carried out according to the manufacturer's instructions. The ALK break-apart probe set kit includes a 250-kb DNA fragment telomeric to ALK (3 0 end) labeled in spectrum orange (red fluorophore) and a 300-kb DNA fragment centromeric to ALK (5 0 end) labeled in spectrum green (green fluorophore). Nuclei were counterstained with DAPI/Vectashield (Vector Laboratories, AbCys, Paris, France). Sections were analyzed under a Â 63 oil immersion objective using a fluorescence microscope. At least 25 cells were analyzed, and up to 50 when a breakapart signal was detected. Nonrearranged ALK appears as split 3 0 and 5 0 signals. Tumors are considered ALK-FISH positive (ALK rearranged) if more than 15% tumor cells show split red and green signals and/or single red signals [38] .
For the detection of the most frequent EML4-ALK transcripts, RNA were extracted from the dissected FFPE tumor areas using the RNeasy FFPE kit (Qiagen).
Reverse transcription was carried out using the High-Capacity cDNA Reverse transcription kit (Applied Biosystems, Foster City, California, USA) in 40 ml reactions and cDNA were analyzed by real-time PCR using the following assays: Hs03654558 (85 bp; E6a/b;A20 EML4-ALK variant), Hs03654556 (79 bp; E13;A20), Hs03654557 (86 bp; E20;A20), HS03654560 (79 bp; E17;A20), and Hs03654559 (80 bp; E18;A20), and Hs03043885 (64 bp; RPL13A) and Hs01108291 (86 bp; POLR2A) as positive controls [39] . RNAs were qualified for EML4-ALK transcript identification by quantitative reverse transcriptase PCR when the cycle thresholds for the positive control gene were below 35.
Results
Clinicopathological results
The mean age of the patients was 60 years (range 40-79) and the male/female ratio was 7/5 ( Table 2 ). The tumors were localized in the right colon (six cases), the transverse colon (one case), the sigmoid (two cases), or the rectum (three cases). A synchronous well-differentiated adenocarcinoma of the colon was present in case 2, but the histology of the metastases showed a high-grade NET.
All of the tumors contained at least one area of large cell NEC characterized by cells with a moderately abundant cytoplasm and a nucleus with coarse chromatin and prominent nucleoli ( Fig. 1 ). According to the WHO grading system, all of the tumors were grade G3 [3] . The mitotic rate within the neuroendocrine component was higher than 20/10 HPF in all cases, except for #4, 9, 10, and 12. In these four latter cases, more than 30% of the tumor cells were Ki-67 positive. In two cases, the neuroendocrine components also contained well-differ-entiated areas, with solid nests of uniform small cells with oval nuclei forming trabeculae or interanastomosing bands with focal rosette-like formations or simply showed solid grouping. There was no particular stroma reaction, but a Crohn's-like reaction was observed in three cases (#1, 2, and 4). In all except one case, many capillary emboli were present in the periphery of the tumor.
The necrosis was extensive in one case, limited in two cases, and absent in the others. In two cases, there was a superficial ulceration. In all except one case, we observed vascular invasion. In five cases, there was a major lymphatic diffusion in the periphery of the tumor, in the mucosa for one, and in the submucosa for the others. Venous extension was present in two cases.
Ten tumors contained an exocrine component that consisted of either adenoma or adenocarcinoma. Two cases (#5 and 6) were NECs with less than 30% exocrine component. The eight remaining cases (#2, 3, 4, and 7 and 9-12) were MANEC with more than 30% of exocrine component. The adenoma/adenocarcinoma component of the tumors was mainly localized within the inner part of the digestive wall, close to the mucosa, as compared with the neuroendocrine component, which was more deeply invasive (Fig. 1) . The other two tumors contained an amphicrine component (#1 and 8).
Immunohistochemical profile
In all cases, alcian blue staining was positive in the exocrine component and negative in the neuroendocrine component. Simultaneous staining with alcian blue and chromogranin A was carried out in one amphicrine carcinoma, and it confirmed that several tumor cells had both exocrine and neuroendocrine differentiation ( Fig. 1) .
In all except one case, the chromogranin A was expressed by 5-80% of tumor cells. The synaptophysin ( Fig. 1 ) and CD56 were negative in one case (amphicrine tumor), but positive in all the other cases, in 50-80% of tumor cells, and 5-80% of tumor cells, respectively.
The CK20 staining was always positive in the exocrine or the amphicrine component of the tumors, but never in the neuroendocrine component.
Tumor dissemination, treatment, and evolution
The lymph nodes contained metastases in 11 of the 12 cases. One patient had lymph node metastases visualized on the CT, but, because of his symptoms, he only underwent a transanal resection and no lymph node was found in the surgical sample.
In six of the nine cases for which at least 12 lymph nodes were available for review, the proportion of involved lymph nodes was higher than 40%. The metastases contained either both exocrine and neuroendocrine components or only the neuroendocrine component.
In one case, we observed only the adenocarcinoma component within a lymph node, but it was a contiguous extension of the carcinoma.
At the time of diagnosis, 10 of the 12 patients had synchronous metastases, and metachronous metastases occurred 8 months after surgery in one of the two cases without initial metastases. Histology of liver metastases was available in 11 cases and the high-grade neuroendocrine component of the primary tumor was present in all cases, either alone (n = 8) or with the exocrine component (n = 3).
The treatment and evolution of the patients are summarized in Table 3 . One patient underwent a transanal resection; the other patients underwent a classical surgery (proctectomy or colectomy), which involved removal of the primary tumor and regional lymph nodes. Two patients with rectal tumors also received radiotherapy before surgery. After surgery, 10 patients received CT, and two patients did not receive CT because they were unlikely to tolerate it because of their poor health status (patients 2 and 8). Two main types of CT were used: 'adenocarcinoma' type (XELOX, FOLFIRI, FOLFOX) or 'high-grade endocrine' type (VP16-CDDP). Altogether, six of 12 patients initially received an 'adenocarcinoma-type' CT.
Three patients showed a partial response. Patient 1 had a regression of 50% of his liver metastases after six cycles of XELOX. Patient 5 showed a partial response after six cycles of VP16-CDDP. Patient 6 showed a major response in terms of the primary tumor as well as liver metastases after 10 cycles of VP16-CDDP. One patient had a stable disease (patient 9); he only had a micrometastasis in one lymph node and no other metastases. For four patients, the response to CT was not evaluable because of clinical progression and poor health status (patients 3, 7, 10, and 11).
All except one patient died because of their cancer (11/12) . The median and mean overall survivals since diagnosis with metastases were 8 and 8.25 months, respectively (range from 1.5 to 22 months). The average survivals for NECs and MANECs were 9 months and 7.9 months, respectively. These data should be interpreted with caution as the number of patients is limited.
Molecular analyses
Tumor DNA containing at least 60% of tumor cells was obtained in 10 cases. BRAF V600E mutations were detected in two cases. KRAS mutations were detected in four cases, corresponding to G12D in two cases and G12V and G13D in the other two ( Table 2 ). In seven cases, DNAs from both exocrine and neuroendocrine components were obtained independently by microdissection of tumor sections. In all cases, both tumor components had the same mutational status (five with KRAS or BRAF mutations and two wild type).
In-situ hybridization was carried out on six samples to detect rearrangements on the ALK locus in tumor cells. In two cases (#12 and 6), a split was detected in 10 and 14% of the tumor cells, and the five other cases (#2, 4, 5 and 9) were normal. According to the criteria used in lung carcinomas to detect EML4-ALK, all tumors were thus considered as negative. Reverse transcriptase PCR carried out on RNA extracted from surgical tumor samples failed to show EML4-ALK transcripts in all cases.
Discussion
We report a retrospective monocentric series of 12 patients with colorectal NEC or MANEC. Eleven patients died of disease progression, despite a partial response to either XELOX or VP16-CDDP CT in three of them. Ten cases had an exocrine component and two others were amphicrine tumors. Half of the tumors had BRAF or KRAS mutations and the mutational status was identical in both components in all cases tested.
The presence of a separately identifiable exocrine component is frequent in NEC of the gastrointestinal tract [40] . In a recent series, an adenocarcinomatous component was detected in 45% of the 65 cases, and among the 37 localized to the colon or the rectum, 20 (31%) had an adenoma and 29 (45%) had an adenocarcinoma [40] . An adenomatous/adenocarcinomatous component was also [23, 26, 41] . All the patients in the present series (n = 12) had an exocrine component, corresponding to adenoma or adenocarcinoma. This high frequency may be because of our extensive tumor sampling of each tumor. Some of our cases had an exocrine component higher than 30% and could thus be subclassified as MANEC. These tumors were not included in NEC in the previous WHO classifications and may have been excluded from NEC published series.
The frequency of NEC of the colon and the rectum may be underestimated in current diagnostic practice. Indeed, the neuroendocrine component may be misinterpreted as a 'solid' or an 'undifferentiated' component of an adenocarcinoma if the expression of neuroendocrine markers is not found by immunohistochemistry. Another cause of the misdiagnosis of colorectal NEC is the sampling of the tumors. Indeed, in all of our cases, the adenocarcinoma component was predominantly localized in the inner layers, whereas the neuroendocrine component was mainly present in the external part of the digestive wall. As most patients have synchronous metastases at the time of diagnosis, some may not undergo surgery and the diagnosis may be made on the basis of superficial endoscopic biopsies. This was the case in one patient of our series (#12), whose initial biopsies of the primary tumor only contained the adenocarcinoma component. Because of the aggressive behavior of these rare tumors and of the necessity to use an aggressive front-line CT, our data indicated that a liver biopsy should be considered when synchronous liver metastases do not appear typical of colorectal adenocarcinoma metastases.
NETs are supposed to derive from neuroendocrine cells, which are normally present within most epithelium. Thus, NETs are clearly individualized from other epithelial proliferations. Treatments of small-cell lung carcinomas are different from those of other lung carcinomas [42] . Recently, NET of the pancreas were shown to have frequent ATRX or DAXX mutations and no KRAS mutations, contrasting with adenocarcinomas of the pancreas that do not have ATRX or DAXX mutations [43] and have more than 60% KRAS mutation.
In this latter study, grade 3 NET (i.e. NEC) cases were excluded from the series. In contrast, previous studies of colorectal MANEC have indicated that neuroendocrine and exocrine components have the same cellular origin. Indeed, analysis of four patients with colorectal NEC or MANEC with three microsatellite markers showed that both components had the same LOH [44] . In three other cases analyzed with 30 microsatellite markers, all the LOH present in the exocrine component were also present in endocrine, but the neuroendocrine component frequently contained additional LOH [14] , indicating that it corresponds to a higher grade transformation of the same tumor. KRAS and BRAF mutations have not been analyzed systematically in colorectal NEC series. The mutational status in exocrine and neuroendocrine components was identical in all the cases tested, confirming that both components derived from the same clone.
The frequency of KRAS/BRAF mutations was 60% in the present series. Although this series is small, this frequency is not different from that published in colorectal adenocarcinomas [45] . Our data indicated that colorectal NEC and adenocarcinomas have common molecular oncogenic pathways. These results are in agreement with histology, which shows a frequent adenomatous component. Altogether, the high frequency of adenoma or adenocarcinoma and the frequency of KRAS/BRAF mutations in colorectal NEC indicate that these cancers share oncogenic mechanisms with adenocarcinomas and could correspond to a high-grade transformation of a pre-existing adenoma.
ALK alterations were investigated recently in NET by insitu hybridization [44] , and EML4-ALK translocation was observed in one of four tumors of the appendix and amplification of the ALK locus in two of seven tumors of the rectum. We thus investigated cases of our series. We detected a split in the ALK locus with in-situ hybridization in two of seven cases, but it was only found in less than 15% of tumor cells, and we detected no EML4-ALK transcripts, indicating that ALK is unlikely to be involved in NEC through common EML4-ALK rearrangements. Thus, colorectal NEC might not benefit from targeted treatment with crisotinib. By contrast, a BRAF p.V600E mutation was detected in two cases. Patients with melanomas with this mutation were shown to benefit from treatment with vemurafenib [45] . Patients with NEC have a very poor prognosis [46] . Eleven of our 12 patients died of disease, with a median survival of 8 months. Very few data are available on the response of mixed endocrine-exocrine carcinomas to cytotoxic drugs, especially in colorectal tumors. Three of our patients showed a partial response, two with VP16-CDDP and one with XELOX. The very poor prognosis of colorectal NEC and the frequency of BRAF mutations warrant investigation studies of vemurafenib treatment in this rare cancer.
We confirmed in this study that the presence of an adenoma and/or an adenocarcinoma is very frequent in colorectal NEC. In addition, we showed that half of NEC had a KRAS/BRAF mutation, as already known for colorectal adenocarcinomas. The same mutation was present in both exoendocrine and neuroendocrine components, indicating that the two components could be derived from the same cell lineage. NEC share oncogenetic pathways with adenocarcinomas and may correspond to a high-grade transformation of colorectal adenomas.
